ClinicalTrials.gg

Program

HER2 Mutant-selective Inhibitor CGT4255

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Cogent Biosciences.

Furthest: phase 1, since Dec 3, 20251 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cogent Biosciences11 open or runningphase 1since Dec 3, 2025Dec 3, 2025May 2028phase 1 · NCT07361562

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07361562 · 100 planned · United States

Ahead

  1. May 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07361562

TargetBeta

ERBB2 →read by rule
“An orally bioavailable mutant-selective inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07361562Carcinoma, Non-Small-Cell Lung · United States1RecruitingMay 2028100

How it is read

Names in the registry

  • “CGT4255”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.